Reata Regains Exclusive Worldwide Rights of its Nrf2 Activator Product Platform from AbbVie

 Reata Regains Exclusive Worldwide Rights of its Nrf2 Activator Product Platform from AbbVie

Reata Regains Exclusive Worldwide Rights of its Nrf2 Activator Product Platform from AbbVie

Shots:

  • AbbVie to receive $330M in cash primarily for bardoxolone, $75M up front in 2019 and the remaining value payable in installments in Q2 and Q4 2020 plus royalties on WW sales of omaveloxolone and certain next-generation Nrf2 activators
  • Reata reacquires WW rights to develop, manufacture and commercialize bardoxolone methyl (ex- Asian markets), omaveloxolone and all other next-generation Nrf2 activators. Reata also signed an amendment to its loan and security agreement with Oxford Finance LLC and Silicon Valley Bank will receive $75M either for positive results of bardoxolone for Alport syndrome or omaveloxolone in patients with Friedreich’s ataxia
  • Bardoxolone and omaveloxolone are investigational candidates targeting transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post